Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleAccepted Article

Gastrointestinal adverse drug reaction profile of etanercept: real world data from patients and healthcare professionals

Jette A. van Lint, Naomi T. Jessurun, Sander W. Tas, Bart J.F. van den Bemt, Michael T. Nurmohamed, Martijn B.A. van Doorn, Phyllis I. Spuls, Astrid M. van Tubergen, Peter M. ten Klooster, Eugene P. van Puijenbroek, Frank Hoentjen and Harald E. Vonkeman
The Journal of Rheumatology May 2021, jrheum.201373; DOI: https://doi.org/10.3899/jrheum.201373
Jette A. van Lint
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naomi T. Jessurun
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sander W. Tas
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bart J.F. van den Bemt
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael T. Nurmohamed
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martijn B.A. van Doorn
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Phyllis I. Spuls
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Astrid M. van Tubergen
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter M. ten Klooster
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eugene P. van Puijenbroek
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Hoentjen
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harald E. Vonkeman
Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, NL; Department of Rheumatology & Clinical Immunology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & immunology Center (ARC), Amsterdam, NL; Department of Pharmacy, Sint Maartenskliniek, Nijmegen NL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, NL; Amsterdam Rheumatology & immunology Center (ARC) | Reade, Amsterdam, NL; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, NL; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, NL; Department of Dermatology, Public Health and Epidemiology; Immunity and Infections, Amsterdam UMC, Location Academic Medical Center, Amsterdam, NL; Department of Rheumatology, Maastricht University Medical Center, Maastricht, NL; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, NL; Transparency in Healthcare B.V., Hengelo, NL; Department of Psychology, Health & Technology, University of Twente, Enschede, NL; Department of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen, NL; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, NL; Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, NL. The Dutch Biologic Monitor was supported by the Netherlands Organisation for Health Research and Development (ZonMw), grant number 848050005. No funding was received for the conduct of this specific study. Corresponding author: Jette A. van Lint,Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, ’s-Hertogenbosch. E-mail: j.vanlint@lareb.nl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective We aimed to describe the nature and frequency of gastrointestinal adverse drug reactions (GI-ADRs) of etanercept (ETN) using patient-reported and healthcare professional (HCP)-registered data and compared this frequency with the GI-ADR frequency of the widely used TNFα-inhibitor adalimumab.

Methods Reported GI-ADRs of ETN for rheumatic diseases were collected from the Dutch Biologic Monitor and DREAM registries. We described the clinical course of GI-ADRs and compared the frequency with adalimumab in both data sources using a Fisher’s exact test.

Results Out of 416 patients using ETN for inflammatory rheumatic diseases in the Dutch Biologic Monitor, 25 patients (6%) reported 36 GI-ADRs. In the DREAM registries 11 GI-ADRs were registered for 9 patients (2.3%), out of 399 patients using ETN, with an incidence of 7.14 per 1000 patient years. Most GI-ADRs concerned diarrhoea, nausea and abdominal pain. GI-ADRs led to ETN discontinuation in one patient (4%) and dose adjustment in four (16%) in the Dutch Biologic Monitor. Eight GI-ADRs (73%) led to ETN discontinuation in the DREAM registries. The frequency of GI-ADRs of ETN did not significantly differ from GI-ADRs of adalimumab in both data sources (Dutch Biologic Monitor: ETN 8.7% vs. ADA 5.3%, p=0.07; DREAM: ETN 2.8% vs. ADA 4.7%, p=0.16).

Conclusion Most GI-ADRs associated with ETN concerned gastrointestinal symptoms. These ADRs may lead to dose adjustment or ETN discontinuation. The frequency of ETN associated GI-ADRs was comparable to the frequency of adalimumab associated GI-ADRs. Knowledge about these previously unknown ADRs can facilitate early recognition and improve patient communication.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 50, Issue 9
1 Sep 2023
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Gastrointestinal adverse drug reaction profile of etanercept: real world data from patients and healthcare professionals
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Accepted manuscript
Gastrointestinal adverse drug reaction profile of etanercept: real world data from patients and healthcare professionals
Jette A. van Lint, Naomi T. Jessurun, Sander W. Tas, Bart J.F. van den Bemt, Michael T. Nurmohamed, Martijn B.A. van Doorn, Phyllis I. Spuls, Astrid M. van Tubergen, Peter M. ten Klooster, Eugene P. van Puijenbroek, Frank Hoentjen, Harald E. Vonkeman
The Journal of Rheumatology May 2021, jrheum.201373; DOI: 10.3899/jrheum.201373

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Accepted manuscript
Gastrointestinal adverse drug reaction profile of etanercept: real world data from patients and healthcare professionals
Jette A. van Lint, Naomi T. Jessurun, Sander W. Tas, Bart J.F. van den Bemt, Michael T. Nurmohamed, Martijn B.A. van Doorn, Phyllis I. Spuls, Astrid M. van Tubergen, Peter M. ten Klooster, Eugene P. van Puijenbroek, Frank Hoentjen, Harald E. Vonkeman
The Journal of Rheumatology May 2021, jrheum.201373; DOI: 10.3899/jrheum.201373
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire